Trial Profile
A phase III study of JNP-0101 in patients with overactive bladder
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 14 Sep 2020
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary)
- Indications Overactive bladder
- Focus Registrational; Therapeutic Use
- Sponsors Juniper Pharmaceuticals
- 14 Jan 2016 New trial record
- 11 Jan 2016 This trial is expected to begin in the first half of 2017. This development program is intended to satisfy the regulatory requirements for approval and will follow the 505(b)(2) regulatory pathway, according to a Juniper Pharmaceuticals media release.